不同免疫细胞和代谢途径在调节胰腺癌免疫反应中的作用（综述）。
Role of different immune cells and metabolic pathways in modulating the immune response in pancreatic cancer (Review).
机构信息
Department of Surgery, Faculty of Health Sciences, University of The Witwatersrand, Johannesburg, Gauteng 2193, South Africa.
出版信息
Mol Med Rep. 2020 Dec;22(6):4981-4991. doi: 10.3892/mmr.2020.11622. Epub 2020 Oct 21.
Abstract
Pancreatic cancer is an aggressive cancer, making it a leading cause of cancer‑related deaths. It is characteristically resistant to treatment, which results in low survival rates. In pancreatic cancer, immune cells undergo transitions that can inhibit or promote their functions, enabling treatment resistance and tumor progression. These transitions can be fostered by metabolic pathways that are dysregulated during tumorigenesis. The present review aimed to summarize the different immune cells and their roles in pancreatic cancer. The review also highlighted the individual metabolic pathways in pancreatic cancer and how they enable transitions in immune cells. Finally, the potential of targeting metabolic pathways for effective therapeutic strategies was considered.
摘要
胰腺癌是一种侵袭性癌症，是癌症相关死亡的主要原因。它的特点是对治疗有抵抗力，导致存活率低。在胰腺癌中，免疫细胞会发生转变，从而抑制或促进其功能，导致治疗耐药和肿瘤进展。这些转变可以通过肿瘤发生过程中失调的代谢途径来促进。本综述旨在总结不同的免疫细胞及其在胰腺癌中的作用。该综述还强调了胰腺癌中个体代谢途径以及它们如何使免疫细胞发生转变。最后，考虑了针对代谢途径作为有效治疗策略的潜力。
相似文献
1
Role of different immune cells and metabolic pathways in modulating the immune response in pancreatic cancer (Review).
Mol Med Rep. 2020 Dec;22(6):4981-4991. doi: 10.3892/mmr.2020.11622. Epub 2020 Oct 21.
2
Pancreatic tumor cell metabolism: focus on glycolysis and its connected metabolic pathways.
Arch Biochem Biophys. 2014 Mar 1;545:69-73. doi: 10.1016/j.abb.2013.12.019. Epub 2014 Jan 3.
3
Metabolism of pancreatic cancer: paving the way to better anticancer strategies.
Mol Cancer. 2020 Mar 2;19(1):50. doi: 10.1186/s12943-020-01169-7.
4
Restoration of miR-340 controls pancreatic cancer cell expression to promote macrophage phagocytosis and enhance antitumor immunity.
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2019-000253.
5
Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.
Cancer Treat Rev. 2014 May;40(4):513-22. doi: 10.1016/j.ctrv.2013.11.005. Epub 2013 Nov 23.
6
Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer.
Am J Physiol Gastrointest Liver Physiol. 2018 Jul 1;315(1):G27-G35. doi: 10.1152/ajpgi.00416.2017. Epub 2018 Mar 15.
7
Functions and clinical implications of exosomes in pancreatic cancer.
Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):75-84. doi: 10.1016/j.bbcan.2018.11.001. Epub 2018 Nov 9.
8
Meet the author: Alice Clare Newman.
Mol Cell. 2021 Jun 3;81(11):2266-2267. doi: 10.1016/j.molcel.2021.05.015.
9
Macrophages in pancreatic cancer: An immunometabolic perspective.
Cancer Lett. 2021 Feb 1;498:188-200. doi: 10.1016/j.canlet.2020.10.029. Epub 2020 Oct 26.
10
Emerging roles of the solute carrier family in pancreatic cancer.
Clin Transl Med. 2021 Mar;11(3):e356. doi: 10.1002/ctm2.356.
引用本文的文献
1
Bibliometric analysis of pancreatic cancer liver metastasis research: global trends, collaborations, and emerging research hotspots.
Front Oncol. 2025 Jul 15;15:1546400. doi: 10.3389/fonc.2025.1546400. eCollection 2025.
2
Immunoregulatory Enzymes.
Acta Naturae. 2025 Jan-Mar;17(1):11-19. doi: 10.32607/actanaturae.27549.
3
In-silico identification of therapeutic targets in pancreatic ductal adenocarcinoma using WGCNA and Trader.
Sci Rep. 2024 Oct 7;14(1):23292. doi: 10.1038/s41598-024-74252-4.
4
Comparative immune profiling of pancreatic ductal adenocarcinoma progression among South African patients.
BMC Cancer. 2024 Jul 7;24(1):809. doi: 10.1186/s12885-024-12595-x.
5
AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
PLoS One. 2023 Nov 9;18(11):e0294065. doi: 10.1371/journal.pone.0294065. eCollection 2023.
6
Exploiting the molecular subtypes and genetic landscape in pancreatic cancer: the quest to find effective drugs.
Front Genet. 2023 Sep 18;14:1170571. doi: 10.3389/fgene.2023.1170571. eCollection 2023.
7
Serum Metabolomic and Lipoprotein Profiling of Pancreatic Ductal Adenocarcinoma Patients of African Ancestry.
Metabolites. 2021 Sep 28;11(10):663. doi: 10.3390/metabo11100663.
8
Targeting Growth Factor Signaling Pathways in Pancreatic Cancer: Towards Inhibiting Chemoresistance.
Front Oncol. 2021 Jun 14;11:683788. doi: 10.3389/fonc.2021.683788. eCollection 2021.
本文引用的文献
1
Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies.
Biomedicines. 2020 Aug 3;8(8):270. doi: 10.3390/biomedicines8080270.
2
Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration.
Theranostics. 2020 May 15;10(14):6231-6244. doi: 10.7150/thno.45219. eCollection 2020.
3
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
Nature. 2020 May;581(7806):100-105. doi: 10.1038/s41586-020-2229-5. Epub 2020 Apr 22.
4
Pancreatic Cancer and Its Microenvironment-Recent Advances and Current Controversies.
Int J Mol Sci. 2020 May 1;21(9):3218. doi: 10.3390/ijms21093218.
5
Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects.
Chronic Dis Transl Med. 2020 Feb 11;6(1):6-17. doi: 10.1016/j.cdtm.2020.01.002. eCollection 2020 Mar.
6
Recent insights into the biology of pancreatic cancer.
EBioMedicine. 2020 Mar;53:102655. doi: 10.1016/j.ebiom.2020.102655. Epub 2020 Mar 2.
7
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy.
World J Gastrointest Oncol. 2020 Feb 15;12(2):173-181. doi: 10.4251/wjgo.v12.i2.173.
8
Mitochondrial TCA cycle metabolites control physiology and disease.
Nat Commun. 2020 Jan 3;11(1):102. doi: 10.1038/s41467-019-13668-3.
9
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.
Future Oncol. 2019 Oct;15(28):3189-3196. doi: 10.2217/fon-2019-0209. Epub 2019 Sep 12.
10
Tissue amino acid profiles are characteristic of tumor type, malignant phenotype, and tumor progression in pancreatic tumors.
Sci Rep. 2019 Jul 8;9(1):9816. doi: 10.1038/s41598-019-46404-4.
Zotero 插件